Insider Trading activities of Macrogenics Inc insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Macrogenics Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Macrogenics Inc since year 2005. Table 2 shows the detailed insider transactions of Macrogenics Inc since 2005. The reporting company's ticker symbol is MGNX. The reporting company's CIK number is 1125345.
The total value of stock buying since 2005 is $922,000.
The total value of stock sales since 2005 is $28,563,241.
The total value of stock option exercises since 2005 is $1,755,752.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Macrogenics Inc (MGNX).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-12 0 $0 0 $0 3,000 $2,820
2017-11 0 $0 5,000 $100,000 5,000 $23,500
2017-10 0 $0 10,000 $200,000 10,000 $47,000
2017-09 0 $0 0 $0 7,000 $6,580
2017-07 0 $0 0 $0 53,264 $65,248
2017-06 0 $0 5,000 $100,000 5,000 $23,500
2017-04 0 $0 15,000 $300,000 15,000 $70,500
2017-01 0 $0 0 $0 84,898 $79,804
2016-10 0 $0 16,231 $475,843 21,580 $57,885
2016-08 0 $0 20,000 $615,600 20,000 $94,000
2016-07 0 $0 13,922 $378,956 13,922 $31,886
2016-05 0 $0 5,000 $125,000 119,517 $112,345
2016-03 10,000 $172,000 0 $0 0 $0
2016-02 0 $0 0 $0 14,462 $13,594
2016-01 0 $0 10,000 $296,400 85,666 $115,717
2015-12 0 $0 0 $0 1,500 $1,410
2015-11 0 $0 10,038 $340,233 1,185 $1,113
2015-10 0 $0 11,233 $262,683 57,919 $426,975
2015-09 0 $0 0 $0 11,000 $10,340
2015-08 0 $0 10,000 $371,500 24,000 $60,160
2015-07 0 $0 14,321 $534,281 20,030 $37,076
2015-06 0 $0 42,581 $1,563,876 17,730 $13,737
2015-05 0 $0 6,233 $188,485 6,233 $4,425
2015-04 0 $0 11,233 $366,097 6,233 $4,425
2015-02 0 $0 5,000 $155,200 5,000 $23,500
2014-12 0 $0 31,892 $1,101,220 108,197 $276,224
2014-11 0 $0 71,247 $1,757,519 70,147 $62,522
2014-10 0 $0 5,000 $102,400 9,660 $27,175
2014-09 0 $0 8,316 $173,721 0 $0
2014-08 0 $0 5,000 $102,600 5,000 $23,500
2014-06 0 $0 8,000 $174,720 8,000 $7,520
2014-05 0 $0 10,946 $216,183 10,946 $7,771
2014-04 0 $0 0 $0 5,000 $23,500
2014-02 0 $0 508,513 $18,560,724 0 $0
2013-10 46,875 $750,000 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Macrogenics Inc insiders (MGNX)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-12-29 Karrels James (SVP, CFO and Secretary) Option Ex 3,000 .94 2,820
2017-11-21 Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) Sale 5,000 20.00 100,000
2017-11-21 Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) Option Ex 5,000 4.70 23,500
2017-10-25 Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) Sale 10,000 20.00 200,000
2017-10-25 Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) Option Ex 10,000 4.70 47,000
2017-09-05 Risser Eric Blasius (Sr VP & Chief Business Officer) Option Ex 2,000 .94 1,880
2017-09-05 Karrels James (SVP, CFO and Secretary) Option Ex 5,000 .94 4,700
2017-07-26 Bonvini Ezio (Sr VP, Research & CSO) Option Ex 53,264 1.23 65,248
2017-06-05 Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) Sale 5,000 20.00 100,000
2017-06-05 Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) Option Ex 5,000 4.70 23,500
2017-04-19 Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) Sale 15,000 20.00 300,000
2017-04-19 Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) Option Ex 15,000 4.70 70,500
2017-01-25 Karrels James (SVP, CFO and Secretary) Option Ex 5,000 .94 4,700
2017-01-17 Koenig Scott (President and CEO) Option Ex 79,898 .94 75,104
2016-10-19 Bonvini Ezio (Sr VP, Research & CSO) Option Ex 5,349 .94 5,028
2016-10-03 Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) Sale 10,000 29.34 293,400
2016-10-03 Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) Option Ex 10,000 4.70 47,000
2016-10-03 Cilinski Lynn (VP, Controller and Treasurer) Sale 6,231 29.28 182,443
2016-10-03 Cilinski Lynn (VP, Controller and Treasurer) Option Ex 6,231 .94 5,857
2016-08-01 Wigginton Jon Marc (Sr VP Clinical Dev & CMO) Sale 20,000 30.78 615,600
2016-08-01 Wigginton Jon Marc (Sr VP Clinical Dev & CMO) Option Ex 20,000 4.70 94,000
2016-07-01 Wigginton Jon Marc (Sr VP Clinical Dev & CMO) Sale 5,000 27.22 136,100
2016-07-01 Wigginton Jon Marc (Sr VP Clinical Dev & CMO) Option Ex 5,000 4.70 23,500
2016-07-01 Cilinski Lynn (VP, Controller and Treasurer) Sale 8,922 27.22 242,856
2016-07-01 Cilinski Lynn (VP, Controller and Treasurer) Option Ex 8,922 .94 8,386
2016-05-27 Cilinski Lynn (VP, Controller and Treasurer) Sale 5,000 25.00 125,000
2016-05-27 Cilinski Lynn (VP, Controller and Treasurer) Option Ex 5,000 .94 4,700
2016-05-16 Koenig Scott (President and CEO) Option Ex 34,619 .94 32,541
2016-05-11 Koenig Scott (President and CEO) Option Ex 79,898 .94 75,104
2016-03-03 Costa Paulo F Buy 10,000 17.20 172,000
2016-02-11 Bonvini Ezio (Sr VP, Research & CSO) Option Ex 11,962 .94 11,244
2016-02-08 Risser Eric Blasius (SVP, Business Development) Option Ex 2,500 .94 2,350
2016-01-29 Karrels James (SVP, CFO and Secretary) Option Ex 10,000 .94 9,400
2016-01-07 Bonvini Ezio (Senior VP, Research) Option Ex 13,316 .94 12,517
2016-01-07 Stein Kathryn E (SVP, Product Dev. & Regulatory) Option Ex 52,350 .89 46,800
2016-01-04 Wigginton Jon Marc (Sr VP, Clinical) Sale 10,000 29.64 296,400
2016-01-04 Wigginton Jon Marc (Sr VP, Clinical) Option Ex 10,000 4.70 47,000
2015-12-23 Risser Eric Blasius (SVP, Business Development) Option Ex 1,500 .94 1,410
2015-11-23 Cilinski Lynn (VP, Controller and Treasurer) Sale 6,921 35.00 242,235
2015-11-23 Cilinski Lynn (VP, Controller and Treasurer) Option Ex 1,185 .94 1,113
2015-11-16 Bonvini Ezio (Senior VP, Research) Sale 3,117 31.44 97,998
2015-10-15 Bonvini Ezio (Senior VP, Research) Sale 6,233 25.21 157,133
2015-10-13 Bonvini Ezio (Senior VP, Research) Option Ex 29,042 13.12 381,031
2015-10-07 Karrels James (SVP, CFO and Secretary) Option Ex 6,000 .94 5,640
2015-10-02 Bonvini Ezio (Senior VP, Research) Option Ex 17,877 .94 16,804
2015-10-01 Wigginton Jon Marc (Sr VP, Clinical) Sale 5,000 21.11 105,550
2015-10-01 Wigginton Jon Marc (Sr VP, Clinical) Option Ex 5,000 4.70 23,500
2015-09-18 Bonvini Ezio (Senior VP, Research) Option Ex 7,000 .94 6,580
2015-09-16 Bonvini Ezio (Senior VP, Research) Option Ex 4,000 .94 3,760
2015-08-27 Bonvini Ezio (Senior VP, Research) Option Ex 5,000 .94 4,700
2015-08-26 Bonvini Ezio (Senior VP, Research) Option Ex 5,000 .94 4,700
2015-08-10 Bonvini Ezio (Senior VP, Research) Option Ex 4,000 .94 3,760
2015-08-03 Wigginton Jon Marc (Sr VP, Clinical) Sale 10,000 37.15 371,500
2015-08-03 Wigginton Jon Marc (Sr VP, Clinical) Option Ex 10,000 4.70 47,000
2015-07-10 Bonvini Ezio (Senior VP, Research) Sale 2,400 38.09 91,416
2015-07-10 Bonvini Ezio (Senior VP, Research) Option Ex 2,400 .71 1,704
2015-07-01 Wigginton Jon Marc (Sr VP, Clinical) Sale 5,000 37.15 185,750
2015-07-01 Wigginton Jon Marc (Sr VP, Clinical) Option Ex 5,000 4.70 23,500
2015-07-01 Cilinski Lynn (VP, Controller and Treasurer) Sale 6,921 37.15 257,115
2015-07-01 Cilinski Lynn (VP, Controller and Treasurer) Option Ex 8,815 .94 8,286
2015-06-30 Bonvini Ezio (Senior VP, Research) Sale 6,497 38.07 247,340
2015-06-30 Bonvini Ezio (Senior VP, Research) Option Ex 6,497 .71 4,612
2015-06-24 Bonvini Ezio (Senior VP, Research) Sale 6,097 38.08 232,173
2015-06-23 Bonvini Ezio (Senior VP, Research) Sale 13,054 38.14 497,879
2015-06-15 Bonvini Ezio (Senior VP, Research) Sale 6,233 34.01 211,984
2015-06-15 Bonvini Ezio (Senior VP, Research) Option Ex 6,233 .71 4,425
2015-06-15 Cilinski Lynn (VP, Controller and Treasurer) Sale 10,700 35.00 374,500
2015-06-15 Cilinski Lynn (VP, Controller and Treasurer) Option Ex 5,000 .94 4,700
2015-05-15 Bonvini Ezio (Senior VP, Research) Sale 6,233 30.24 188,485
2015-05-15 Bonvini Ezio (Senior VP, Research) Option Ex 6,233 .71 4,425
2015-04-15 Bonvini Ezio (Senior VP, Research) Sale 6,233 33.98 211,797
2015-04-15 Bonvini Ezio (Senior VP, Research) Option Ex 6,233 .71 4,425
2015-04-01 Wigginton Jon Marc (Sr VP, Clinical) Sale 5,000 30.86 154,300
2015-02-02 Wigginton Jon Marc (Sr VP, Clinical) Sale 5,000 31.04 155,200
2015-02-02 Wigginton Jon Marc (Sr VP, Clinical) Option Ex 5,000 4.70 23,500
2014-12-24 Karrels James (VP, CFO and Secretary) Option Ex 4,100 .94 3,854
2014-12-22 Risser Eric Blasius (VP, Business Development) Option Ex 10,000 19.59 195,950
2014-12-22 Stein Kathryn E (SVP, Product Dev. & Regulatory) Sale 10,946 37.00 405,002
2014-12-22 Stein Kathryn E (SVP, Product Dev. & Regulatory) Option Ex 10,946 .07 777
2014-12-19 Koenig Scott (President and CEO) Option Ex 62,205 .94 58,472
2014-12-18 Risser Eric Blasius (VP, Business Development) Sale 10,000 33.50 335,000
2014-12-18 Risser Eric Blasius (VP, Business Development) Option Ex 10,000 .94 9,400
2014-12-18 Stein Kathryn E (SVP, Product Dev. & Regulatory) Sale 10,946 33.00 361,218
2014-12-18 Stein Kathryn E (SVP, Product Dev. & Regulatory) Option Ex 10,946 .71 7,771
2014-11-24 Risser Eric Blasius (VP, Business Development) Sale 10,000 27.75 277,500
2014-11-24 Risser Eric Blasius (VP, Business Development) Option Ex 10,000 .94 9,400
2014-11-21 Stein Kathryn E (Senior VP, Prd Dev & Reg Aff) Sale 10,946 27.00 295,542
2014-11-21 Stein Kathryn E (Senior VP, Prd Dev & Reg Aff) Option Ex 10,946 .71 7,771
2014-11-17 Stein Kathryn E (Senior VP, Prd Dev & Reg Aff) Sale 2,090 22.95 47,965
2014-11-17 Stein Kathryn E (Senior VP, Prd Dev & Reg Aff) Option Ex 2,090 .94 1,964
2014-11-14 Bonvini Ezio (Senior VP, Research) Option Ex 3,900 .71 2,769
2014-11-14 Stein Kathryn E (Senior VP, Prd Dev & Reg Aff) Sale 23,211 23.33 541,512
2014-11-14 Stein Kathryn E (Senior VP, Prd Dev & Reg Aff) Option Ex 23,211 .94 21,818
2014-11-13 Risser Eric Blasius (VP, Business Development) Sale 10,000 25.00 250,000
2014-11-13 Risser Eric Blasius (VP, Business Development) Option Ex 10,000 .94 9,400
2014-11-12 Risser Eric Blasius (VP, Business Development) Sale 15,000 23.00 345,000
2014-11-12 Risser Eric Blasius (VP, Business Development) Option Ex 10,000 .94 9,400
2014-10-10 Bonvini Ezio (Senior VP, Research) Option Ex 400 .71 284
2014-10-09 Bonvini Ezio (Senior VP, Research) Option Ex 2,663 .71 1,890
2014-10-08 Bonvini Ezio (Senior VP, Research) Option Ex 1,597 .94 1,501
2014-10-01 Wigginton Jon Marc (Sr V.P., Clinical) Sale 5,000 20.48 102,400
2014-10-01 Wigginton Jon Marc (Sr V.P., Clinical) Option Ex 5,000 4.70 23,500
2014-09-02 Risser Eric Blasius (VP, Business Development) Sale 8,316 20.89 173,721
2014-08-18 Wigginton Jon Marc (Senior VP, Clinical Dev.) Sale 5,000 20.52 102,600
2014-08-18 Wigginton Jon Marc (Senior VP, Clinical Dev.) Option Ex 5,000 4.70 23,500
2014-06-30 Risser Eric Blasius (VP, Business Development) Sale 8,000 21.84 174,720
2014-06-30 Risser Eric Blasius (VP, Business Development) Option Ex 8,000 .94 7,520
2014-05-29 Stein Kathryn E (Senior VP, Prd Dev & Reg Aff) Sale 10,946 19.75 216,183
2014-05-29 Stein Kathryn E (Senior VP, Prd Dev & Reg Aff) Option Ex 10,946 .71 7,771
2014-04-01 Wigginton Jon Marc (Sr VP, Clinical) Option Ex 5,000 4.70 23,500
2014-02-18 Hurwitz Edward (Director) Sale 308,513 36.50 11,260,724
2014-02-18 Oronsky Arnold L (Director) Sale 200,000 36.50 7,300,000
2013-10-16 Galbraith Kenneth (Director) Buy 46,875 16.00 750,000

Insider trading activities including stock purchases, stock sales, and option exercises of MGNX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Macrogenics Inc (symbol MGNX, CIK number 1125345) see the Securities and Exchange Commission (SEC) website.